Study Finds Birth Hypoxia May Increase ADHD Likelihood
January 27, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Tepadina
(United States) [Available] ,Tepylute
(United States) [Available]Synonyms :
Thiotepa
Class :
ethylenimine
Brand Name :
Tepadina
(United States) [Available] ,Tepylute
(United States) [Available]Synonyms :
Thiotepa
Class :
ethylenimine
Dosage Forms & Strengths
Powder for injection
15mg
30mg
100mg
0.3 - 0.4
mg/kg
Intravenous (IV)
one time only
1 - 4
weeks
0.3 - 0.4
mg/kg
Intravenous (IV)
1 - 4
weeks
30 - 60
mg
by intravesical instillation done into the bladder once, and retained for 2hrs, if the patient cannot maintain 60 ml for 2hrs, and given in a volume of 30 ml The therapy is recommended once a week for four weeks, and the treatment may be repeated if necessary but given with caution
Dosage Forms & Strengths
powder for injection
15mg
30mg
100mg
25 - 65
mg/m^2
Intravenous (IV)
3 - 4
weeks
Dosage Forms & Strengths
powder for injection
15mg
30mg
100mg
The dose selection for patients above 65 years old needs to be cautious, as their renal and hepatic function is weaker Hence starting with the lower dose is recommended
adenovirus types and live oral
when adenovirus type 7 vaccine live is combined with thiotepa, the risk or severity of infection increases
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection
when thiotepa and deferiprone combine, the toxicity of both drugs increases by synergism
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection
influenza virus vaccine quadrivalent adjuvanted
when thiotepa and influenza virus vaccine quadrivalent, adjuvanted combine, thiotepa decreases the effects of the vaccine by antagonism
influenza virus vaccine trivalent adjuvanted
when thiotepa and influenza virus vaccine trivalent, adjuvanted combine, thiotepa reduces the impact of the vaccine by antagonism
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection
when used in combination with thiotepa, the therapeutic efficacy of palifermin decreases by thiotepa
when used in combination with thiotepa, the therapeutic efficacy of ropeginterferon alfa 2b can decrease by thiotepa
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection
when thiotepa and tofacitinib combine, the immunosuppressive effects of both the drugs are enhanced and lead to an increased risk of infection
when both the drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, there may be an increased risk or severity of adverse effects
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of thiotepa and reduce the the bioavailability of thiotepa
when thiotepa and belatacept combine, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection
when thiotepa and bendamustine combine, the toxicity of both drugs increases by synergism
when thiotepa and busulfan combine, the toxicity of both drugs increases by synergism
when thiotepa and carmustine combine, the toxicity of both drugs increases by synergism
when thiotepa and chlorambucil combine, the toxicity of both drugs increases by synergism
when thiotepa and cholera vaccine combines, thiotepa decreases the effects of the vaccine by antagonism
when thiotepa and cisplatin combine, the toxicity of both drugs increases by synergism
when thiotepa and cyclophosphamide combine, the toxicity of both drugs increases by synergism
when thiotepa and dacarbazine combine, the toxicity of both drugs increases by synergism
when thiotepa and dengue vaccine combines, thiotepa decreases the effects of the vaccine by immunosuppressive effects
when thiotepa and denosumab combine, the risk or severity of adverse effects increases
when thiotepa and eluxadoline combine, thiotepa increases levels of eluxadoline by affecting the enzyme cyp2b6 metabolism
when thiotepa and fingolimod combine, thiotepa increases the effects of fingolimod by immunosuppressive effects
when both drugs are combined, the risk or severity of adverse effects increases
when combined with ifosfamide, the metabolism of thiotepa increases
when thiotepa and influenza a (h5n1) vaccine combine, thiotepa decreases the effects of the vaccine by antagonism
influenza virus vaccine (h n ) adjuvanted
when thiotepa and influenza virus vaccine (h5n1), adjuvanted combine, thiotepa decreases the effects of the vaccine by antagonism
when thiotepa and lomustine combine, the toxicity of both drugs increases by synergism
when thiotepa and mechlorethamine combine, thiotepa increases the risk of immunosuppression and myelosuppression by synergism
when thiotepa and meningococcal group b vaccine combine, thiotepa decreases the effects of the vaccine by antagonism
when thiotepa and ofatumumab sc combine, the immunosuppressive effects of both the drugs are enhanced and lead to an increased risk of infection
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection
when thiotepa and streptozocin combine, the toxicity of both drugs increases by synergism
when thiotepa and trastuzumab combine, the immunosuppressive effects of both the drugs are enhanced and lead to an increased risk of infection
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection
when thiotepa and zidovudine combine, the toxicity of both drugs increases by synergism
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
It may enhance the serum concentration when combined with alkalinizing agents
thiotepa: they may enhance serum concentrations of CYP3A4 Inducers
thiotepa: they may enhance serum concentrations of CYP3A4 Inducers
thiotepa: they may enhance serum concentrations of CYP3A4 Inducers
thiotepa: they may enhance serum concentrations of CYP3A4 Inducers
thiotepa: they may enhance serum concentrations of CYP3A4 Inducers
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Ethylenimine
when both drugs are combined, there may be an increased risk or severity of adverse effects
it may increase the level of serum concentration of memantine
It may enhance the serum concentration when combined with alkalinizing agents
It may diminish the excretion when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
bazedoxifene/conjugated estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Ergot alkaloids
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Endothelin receptor antagonists
It may diminish the metabolism when combined with Estrogens
It may diminish the metabolism when combined with Estrogens
It may enhance the risk of adverse reactions when combined with Ethylenimine
It may enhance the risk of adverse reactions when combined with Ethylenimine
It may enhance the risk of adverse reactions when combined with Ethylenimine
It may enhance the risk of adverse reactions when combined with Ethylenimine
It may enhance the risk of adverse reactions when combined with Ethylenimine
when two drugs are combined, the metabolism of thiotepa increases
Actions and Spectrum:
Actions:
Thiotepa is an alkylating agent, like nitrogen mustard. It damages DNA. Thiotepa releases ethyleneimine radicals which interfere with DNA bonds, similar to radiation. A major way Thiotepa disrupts DNA is by alkylating guanine at the N-7 position, causing the purine base to break off from the sugar, releasing alkylated guanines.
Spectrum:
Thiotepa is FDA-approved to treat bladder, breast, ovarian cancers, and cancerous fluid buildup around lungs, heart, abdomen. However, researchers explore using Thiotepa for other cancers, like bone marrow and stem cell transplant protocols, expanding its uses.
Adverse drug reactions:
Frequency defined
>10%
Graft versus host disease
Elevated hepatic enzymes
Hemorrhagic cystitis
Stomatitis
Hyperbilirubinemia
Exfoliative dermatitis
<10%
Intracranial bleeding
Infection
GI bleeding
Veno-occlusive disease
Sinusoidal obstruction syndrome
Black Box Warning:
Thiotepa chemotherapy can severely decrease white blood cells, red blood cells, platelets, raising infection, fatigue, bleeding risks. In over 10% of patients, Thiotepa caused mouth sores, diarrhea, throat irritation, rash, blood in urine, liver issues. Life-threatening risks include bone marrow failure, allergic reactions, liver dysfunction, veno-occlusive disease, neurological effects, and new cancer risk. Seek immediate medical help for allergic reactions, liver or neurological symptoms, as high Thiotepa doses worsen these side effects.
Contraindication/Caution:
Contraindications
Cautions
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Pharmacology:
Thiotepa is a drug. It limits the growth of cancer cells by breaking their DNA. First, it acts like radiation. It releases chemicals that cut DNA strands. It changes guanine, a DNA building block, at a specific spot. And, thiotepa stops DNA from forming right. So, cancer cells can’t multiply and grow. That stops cancers like bladder, breast, ovarian, and fluid-filled tumors from spreading. But, scientists still study thiotepa. They want to know if it can treat other cancers too. It may also help patients before stem cell transplants.
Pharmacodynamics:
Thiotepa is toxic to cells. It works similarly to nitrogen mustard, which is a chemical weapon. Thiotepa acts like radiation. It releases compounds that damage DNA bonds. The compounds alter guanine, a DNA piece, in a key area. This leads to breaks and dislodges guanine parts.
Pharmacokinetics:
Distribution:
Around 10-20% of thiotepa attaches to proteins inside your body. The amount distributed ranges from 1.0 to 1.9 liters per kilogram of body weight.
Metabolism:
The liver breaks down thiotepa.
Elimination and Excretion
Thiotepa itself has a half-life around 2.4 hours. The broken-down form lasts 17.6 hours. Thiotepa leaves mostly through urine.
Administration:
Thiotepa is injected into veins or cavities like the bladder. A healthcare professional administers the injection. For bladder injections, you need to retain it for 2 hours. Inform caregivers if you experience discomfort, to adjust the dose. Dosing occurs every 1 to 4 weeks, as per your doctor’s instructions. Due to bleeding and infection risks, frequent tests are necessary. Avoid contact with mouth, eyes, nose, or skin – it can cause harm. Thoroughly clean skin and change bandages at least 48 hours after each dose to minimize side effects. Additionally,change bedsheets daily during treatment.
Patient Information Leaflet
Pronunciation: Thye-oh-tep-a
Use: Thiotepa is a chemotherapy medication. It belongs to the alkylating agents class. Thiotepa treats cancers such as bladder, ovarian, and leptomeningeal metastasis. It is used for bone marrow transplants as intravenous therapy. Thiotepa disrupts DNA bonds in cells, stopping cancer cell growth and division. As an anti-cancer drug, it targets cancerous cells, inhibiting their rapid multiplication. Thus, it helps manage and treat malignancies.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
